Shanghai Kehua Bio-engineering Co., Ltd.
002022.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.19B
Close$
$-0.61
110.7% downside
Current Fair Value
110.7% downsideOvervalued by 110.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.19 Billion |
|---|---|
| Enterprise Value | $3.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.25 |
| Outstanding Shares | 514,583,537 |
Return
| Return on Equity | -27.92% |
|---|---|
| Return on Assets | -15.70% |
| Return on Invested Capital | -22.95% |
Valuation & Multiples
| P/E Ratio | -4.54 |
|---|---|
| PEG | 14.65 |
| Price to Sales | 1.9 |
| Price to Book Ratio | 1.14 |
| Enterprise Value to Revenue | 1.82 |
| Enterprise Value to EBIT | -4.25 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 21, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$522.67 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Kehua Bio-engineering Co., Ltd.
1,870 employees
CEO: Li Ming Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. T...